![](https://endpts.com/wp-content/uploads/2022/03/Andrew-Obenshain-bluebird-bio-tile-scaled.jpg)
Andrew Obenshain, bluebird bio CEO
Bluebird is still looking for more financing as it brings sickle cell therapy to market: #JPM24
SAN FRANCISCO — After striking deals for as much as $225 million in financing, bluebird bio’s CEO said the company is still on the lookout for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.